Adalimumab treatment for SAPHO syndrome.

© 2010 The Authors. doi: 10.2340/00015555-0822 Journal Compilation © 2010 Acta Dermato-Venereologica. ISSN 0001-5555 SAPHO syndrome is a rare condition of unknown pathogenesis originally described by Chamot et al. (1) in 1987. Onset usually occurs in young adults, with no differences between sexes and it is manifested by synovitis, acne, pustulosis, hyperostosis and osteitis. Of paramount importance is the finding of a non-infectious, inflammatory osteitis associated with skin lesions. Since there is no accepted universal treatment for SAPHO syndrome, several therapies have been used to treat this disorder, such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, immunosuppressants and immunomodulators, with varying results. Antitumour necrosis factor (TNF)-α agents have recently been employed in this syndrome, yielding an excellent response (2).